“Rajeev Shah”

As a Name:  Registrant, Group Member and/or Signatory

        

Latest Filing:  4/25/24  as  ↓Group Member

As:  Registrant

        

As:  Group Member  (Co-Filer Non-Registrant:  Partner, Affiliate, etc.)

“Rajeev Shah” has been a Group Member with  one  Filer:

        

As Of	Filer			Filings       #        Latest		Issuer     (Primary)
4/25/24		MA	Ra Capital Management, L.P.	418	SC 13G	NY	Protara Therapeutics, Inc.

“Rajeev Shah” has/had a Group Member interest in  151  Issuers:

As Of	Issuer			Filings       #        Latest		With Filer     (Primary)
4/25/24		NY	Protara Therapeutics, Inc.	1	SC 13G	MA	Ra Capital Management, L.P.
4/15/24		CA	Surrozen, Inc./DE	1	SC 13G	MA	Ra Capital Management, L.P.
4/12/24		DE	Eliem Therapeutics, Inc.	5	SC 13D/A	MA	Ra Capital Management, L.P.
4/12/24		CA	Boundless Bio, Inc.	1	SC 13G	MA	Ra Capital Management, L.P.
4/11/24		MA	CervoMed Inc.	1	SC 13G	MA	Ra Capital Management, L.P.
4/11/24		MA	Acrivon Therapeutics, Inc.	3	SC 13D/A	MA	Ra Capital Management, L.P.
4/4/24		MA	Dyne Therapeutics, Inc.	4	SC 13G	MA	Ra Capital Management, L.P.
4/1/24		UT	Sera Prognostics, Inc.	1	SC 13G	MA	Ra Capital Management, L.P.
3/29/24		CA	Nkarta, Inc.	3	SC 13D/A	MA	Ra Capital Management, L.P.
3/29/24		CA	ARS Pharmaceuticals, Inc.	5	SC 13D/A	MA	Ra Capital Management, L.P.
3/29/24		CA	Alto Neuroscience, Inc.	1	SC 13G	MA	Ra Capital Management, L.P.
3/28/24		CA	LENZ Therapeutics, Inc.	1	SC 13D	MA	Ra Capital Management, L.P.
3/25/24		CA	Regulus Therapeutics Inc.	1	SC 13G	MA	Ra Capital Management, L.P.
3/25/24			Cybin Inc.	1	SC 13G	MA	Ra Capital Management, L.P.
3/11/24		MA	PepGen Inc.	4	SC 13D/A	MA	Ra Capital Management, L.P.
3/6/24		CA	Janux Therapeutics, Inc.	2	SC 13D/A	MA	Ra Capital Management, L.P.
3/6/24		CA	89bio, Inc.	9	SC 13D/A	MA	Ra Capital Management, L.P.
2/27/24			Connect Biopharma Holdings Ltd.	6	SC 13D/A	MA	Ra Capital Management, L.P.
2/26/24		PA	Larimar Therapeutics, Inc.	4	SC 13G	MA	Ra Capital Management, L.P.
2/22/24		CA	Cytek Biosciences, Inc.	5	SC 13G	MA	Ra Capital Management, L.P.
			More...  Please Sign In to list all 151 of them.

“Rajeev Shah” has been a Group Member with  4  other Group Members:

As Of	Group Member			Filings       #        Latest		With Filer     (Primary)		Issuer     (Primary)
4/25/24		MA	Peter Kolchinsky	418	SC 13G	MA	Ra Capital Management, L.P.	NY	Protara Therapeutics, Inc.
		MA	Ra Capital Healthcare Fund, L.P.	355
2/13/24		MA	Ra Capital Nexus Fund, II L.P.	2	SC 13D/A	MA	Ra Capital Management, L.P.	MA	PepGen Inc.
9/29/23		MA	Ra Capital H Ealthcare Fund, L.P.	2	SC 13G	MA	Ra Capital Management, L.P.	NC	Chimerix Inc.

As:  Signatory  (Director, Officer, Attorney, Accountant, Banker, Agent, etc.)

“Rajeev Shah” has been a Signatory for/with  39  Filers:

        

As Of	Filer			Filings       #        Latest		Issuer     (Primary)
4/25/24		MA	Ra Capital Management, L.P.	348	SC 13G	NY	Protara Therapeutics, Inc.
4/5/24		NY	Protara Therapeutics, Inc.	1	8-K	—
3/13/24		MA	Solid Biosciences Inc.	22	S-3	—
3/6/24		CA	Boundless Bio, Inc.	2	S-1	—
1/22/24		MA	Dianthus Therapeutics, Inc./DE	1	8-K	—
1/18/24		CA	CG Oncology, Inc.	3	S-1/A	—
11/27/23		CT	Arvinas, Inc.	1	8-K	—
11/17/23			Structure Therapeutics Inc.	1	10-Q	—
11/17/23		CA	Carmot Therapeutics Inc.	2	S-1	—
8/28/23		MA	Apogee Therapeutics, Inc.	3	10-Q	—
6/20/23		CA	DICE Therapeutics, Inc.	2	8-K	—
5/26/23			Legend Biotech Corp.	1	F-3ASR	—
5/2/23		MA	ImmunoGen, Inc.	1	8-K	—
4/28/23		NC	Satsuma Pharmaceuticals, Inc.	11	10-K/A	—
3/9/23		MA	Black Diamond Therapeutics, Inc.	8	S-8	—
8/23/22		CA	Third Harmonic Bio, Inc.	2	S-1	—
3/4/22		CA	AN2 Therapeutics, Inc.	2	S-1	—
3/3/22		MA	Concert Pharmaceuticals, Inc.	2	10-K	—
1/4/22		MA	Affinia Therapeutics Inc.	2	S-1	—
10/1/21		MA	Xilio Therapeutics, Inc.	2	S-1	—
			More...  Please Sign In to list all 39 of them.

“Rajeev Shah” has/had a Signatory interest in  141  Issuers:

As Of	Issuer			Filings       #        Latest		With Filer     (Primary)
4/25/24		NY	Protara Therapeutics, Inc.	1	SC 13G	MA	Ra Capital Management, L.P.
4/15/24		CA	Surrozen, Inc./DE	1	SC 13G	MA	Ra Capital Management, L.P.
4/12/24		DE	Eliem Therapeutics, Inc.	5	SC 13D/A	MA	Ra Capital Management, L.P.
4/12/24		CA	Boundless Bio, Inc.	1	SC 13G	MA	Ra Capital Management, L.P.
4/4/24		MA	Dyne Therapeutics, Inc.	3	SC 13G	MA	Ra Capital Management, L.P.
4/1/24		UT	Sera Prognostics, Inc.	1	SC 13G	MA	Ra Capital Management, L.P.
3/29/24		CA	Alto Neuroscience, Inc.	1	SC 13G	MA	Ra Capital Management, L.P.
3/28/24		CA	LENZ Therapeutics, Inc.	1	SC 13D	MA	Ra Capital Management, L.P.
3/25/24			Cybin Inc.	1	SC 13G	MA	Ra Capital Management, L.P.
3/11/24		MA	PepGen Inc.	4	SC 13D/A	MA	Ra Capital Management, L.P.
3/6/24		CA	Janux Therapeutics, Inc.	2	SC 13D/A	MA	Ra Capital Management, L.P.
3/6/24		CA	89bio, Inc.	8	SC 13D/A	MA	Ra Capital Management, L.P.
2/27/24			Connect Biopharma Holdings Ltd.	6	SC 13D/A	MA	Ra Capital Management, L.P.
2/26/24		PA	Larimar Therapeutics, Inc.	4	SC 13G	MA	Ra Capital Management, L.P.
2/22/24		CA	Cytek Biosciences, Inc.	5	SC 13G	MA	Ra Capital Management, L.P.
2/21/24		WA	Icosavax, Inc.	2	SC 13D/A	MA	Ra Capital Management, L.P.
2/14/24		MA	EyePoint Pharmaceuticals, Inc.	3	SC 13G/A	MA	Ra Capital Management, L.P.
2/14/24			Orchard Therapeutics plc	5	SC 13G/A	MA	Ra Capital Management, L.P.
2/14/24		MA	Werewolf Therapeutics, Inc.	5	SC 13D/A	MA	Ra Capital Management, L.P.
2/14/24		NY	Tourmaline Bio, Inc.	2	SC 13G/A	MA	Ra Capital Management, L.P.
			More...  Please Sign In to list all 141 of them.